Skip to main content
OpenTrials
Completed

NCT Number: NCT01368614

AVAPS-AE Efficacy Study

The purpose of this study is to evaluate the feasibility of using of the Average Volume Assured Pressure Support (AVAPS-AE) mode versus Continuous Positive Airway Pressure (CPAP) and bilevel pressure support ventilation (PSV) modes of ventilation in patients diagnosed with Obesity Hypoventilation syndrome (OHS).

The investigators believe the use of the AVAPS-AE mode of ventilation after 6 weeks will yield daytime gas exchange values which are equivalent or no worse when compared to using CPAP and bilevel PSV modes of ventilation in the OHS population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Arizona School of Medicine, Tucson, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age greater than or equal to 18 years of age; less than or equal to 70 years of age
  • Diagnosis of Obesity Hypoventilation Syndrome via a diagnostic sleep study in the past 3 months but have not initiated therapy
  • BMI greater than or equal to 30 kg/m2
  • Daytime PaCO2 greater than or equal to 45 mmHg
  • Apnea Hypopnea index (AHI) > 5
  • Daytime pH > 7.35
  • Forced Expiratory Volume at 1 second / forced vital capacity (FEV1/FVC) > 70%

Exclusion criteria

  • Acutely ill, medically complicated or who are medically stable, or as otherwise determined by the investigator
  • Respiratory alkalosis (pH > 7.45), per investigator discretion
  • Emergency admissions on chronic respiratory failure
  • Hospitalization for respiratory exacerbation < 6 weeks prior to screening visit
  • Participants in whom PAP therapy is otherwise medically contraindicated
  • Impaired upper airway function. For example, obstruction due to infections(laryngitis, epiglottis), craniofacial malformations, tumors, uvulopalatopharyngoplasty, presence of tracheostomy, or bilateral vocal cord palsy that does not allow tolerance of Non-invasive positive pressure ventilation (NPPV)
  • Facial trauma, burns, surgery or anatomical abnormalities interfering with mask fit.

Treatment and study plan

AVAPS-AE Mode of Therapy

Device

AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.

Respironics OnmiLab BiPAP S mode

Device

Currently cleared Non-Invasive Ventilation (NIV) therapy modality

Respironics OmniLab Advanced CPAP mode

Device

Currently cleared NIV therapy modality

Primary outcomes

  1. Daytime Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2)

    Time frame: Screening & 6 weeks

    Daytime PaCO2 measurements will be assessed for all randomized patients to each mode of ventilation therapy (AVAPS-AE, bilevel PSV, CPAP) after 6 weeks.

Secondary outcomes

  1. Daytime Partial Pressure of Oxygen in Arterial Blood(Pa02)

    Time frame: Screening & 6 weeks

    Daytime Pa02 measurements will be assessed for all randomized patients to each mode of ventilation therapy (AVAPS-AE, bilevel PSV, CPAP) after 6 weeks.

  2. Apnea Hypopnea Index (AHI)

    Time frame: Screening & 6 weeks

    The AHI is the number of apneas and hypopneas per hour of sleep. It will be evaluated during the screening sleep study and the 6 week follow up sleep study. AHI less than 5 is considered normal. For an Apnea-Hypopnea Index (or AHI) from 5 to 15 denotes mild sleep apnea. Fifteen to 30 is moderate, while a greater than 30 AHI is considered severe.

  3. Epworth Sleepiness Scale

    Time frame: Screening & 6 weeks

    Epworth Sleepiness scale is a measure of daytime sleepiness. It is a series of 8 questions answered on a scale of 0 to 3, 0 being no chance of dozing and 3 being a high chance of dozing. The range of the scale is 0 to 24. The higher the total score, the higher the chance of falling asleep.

  4. Severe Respiratory Insufficiency Questionnaire (SRIQ)

    Time frame: Screening & 6 weeks

    The SRIQ is a 49 question survey. This survey asks questions about the past week. It is answered on a scale of -2 to 2 and converted to 1 to 5, 1 is completely untrue and 5 is always true. The questionnaire is broken down into 7 sections when scoring: respiratory complaints, physical functioning, attendant systems and sleep, social relationships, anxiety, psychological well-being and social functioning. Once each scale score is calculated. The average score can be calculated by taking the mean of the subscales. This process of transformation produces a score between 0 and 100 with higher values indicating a better health-related quality of life according to content of the scale.

  5. Ventilator Adherence - Average Hours

    Time frame: 6 weeks

    The average number of hours ventilator was used per each day used.

  6. Ventilator Adherence - Days Used

    Time frame: 6 weeks

    Average number of days used per week

  7. Actigraphy

    Time frame: Screening & 6 weeks

    Actigraphy is a method of measuring activity and sleep which is achieved by wearing a small watch-like device for an extended period of time. The data is intended to provide an objective measure of physical activity and sleep / week patterns during pre / post sleep studies and throughout the 6 weeks of home use.

  8. Room Air Sp02 Assessment Via Pulse Oximetry

    Time frame: Screening & 6 weeks

    Oxygen saturation measurements as determined by pulse oximetry

  9. Nocturnal Transcutaneous Capnography (TcC02)

    Time frame: Screening & 6 weeks

    Nocturnal Transcutaneous Capnography is a non-invasive monitoring tool to measure ventilation over the night.

    .

  10. Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study) - Duration

    Time frame: Screening & 6 weeks

    Duration, efficiency and quality of sleepiness are measured by a number of different parameters. Total sleep time in each stage provides the average amount of time a participant was in that stage of sleep. This includes Stage 1, Stage 2, Stage 3/4, and Rapid Eye Movement (REM) sleep.

  11. Duration and Quality of Sleep and Sleepiness (Derived From Sleep Study) - Sleep Efficiency

    Time frame: Screening & 6 weeks

    Duration, efficiency and quality of sleepiness are measured by a number of different parameters. Sleep efficiency is measured by the total time a participant is spent asleep.

  12. Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study)- Arousal and Awakening Indices

    Time frame: Screening & 6 weeks

    The arousal index is measured by the average number of arousals or awakenings a participant has over an hour of sleep.

  13. Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study)- Nocturnal O2 Saturation

    Time frame: Screening & 6 weeks

    Measurement of overnight oxygen saturation as measured by percentage of oxygen saturation (SpO2)

  14. Reaction Time (Psychomotor Vigilance Test-PVT)

    Time frame: Screening & 6 weeks

    To measure trends of vigilance between the baseline screening assessment and the 6 week follow up visit comparing the three Arms/Groups. This measured how quickly participants reacted to visual stimulus. Reaction time is the latency at which the participant reacts to a visual stimulus > 100 ms.

  15. Number of Participants With Need for Continued Oxygen Supplementation

    Time frame: Screening & 6 weeks

    Some users enrolled into the study required supplemental oxygen at different times during the day: at rest, during exertion and at night. The need for supplemental oxygen was compared at baseline and at 6 weeks.

Sponsors and collaborators

Lead sponsor

Philips Respironics

Industry

Registry information

Official study title

Randomized Controlled Trial Evaluating the Feasibility of AVAPS-AE vs. CPAP vs.Bilevel Pressure Support Ventilation in Obesity Hypoventilation Syndrome

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Jun 8, 2011
Registry last updated
Apr 26, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.